FGF2 and breast carcinoma: Similar to the breast cancer model, anti-VEGF and imatinib combination therapy increased the necrotic area in FGF-2− tumors, whereas this therapeutic regiment had no effect on necrosis of FGF-2+ tumors (Supplementary Fig. 5a, b).